Tag Archive | "Eisai"

Eisai returns EZH2 program, including EPZ-6438 to Epizyme

Tags: , , ,


Epizyme has reacquired global rights to its EZH2 program, including EPZ-6438, from its partner Eisai Read the full story

Eisai and Merck in solid tumour triple therapy pact

Tags: , , ,


Eisai and Merck announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck’s anti-PD-1 therapy, pembrolizumab Read the full story

Emergent acquires Eisai’s EV-035 series technology

Tags: , , ,


Evolva Holding announced that Emergent BioSolutions has acquired Evolva’s anti-bacterial programme, the EV-035 series Read the full story

Hikma and Eisai form a pharma partnership for Fycompa

Tags: , , ,


Hikma Pharmaceuticals announces a pharma partnership with Eisai for the distribution of Fycompa. Read the full story

FSC Therapeutics signs a pharma deal with Eisai

Tags: , , ,


FSC Therapeutics has entered into a transaction with Eisai Inc. to acquire exclusive U.S. marketing rights for AcipHex Sprinkle (rabeprazole sodium). Read the full story

Top 50 Pharma (top pharmaceutical companies)

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,


The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

Eisai

Tags: ,


Eisai is a top pharmaceutical company based in Tokyo, Japan Read the full story

Licensing agreement for E7727

Tags: , ,


Otsuka has acquired rights from Eisai Inc. to develop and sell in the US, Canada and Japan the DNA methylation inhibitor Dacogen®. Read the full story

Eisai and Biogen Idec ink a pharma deal for Alzheimer’s disease

Tags: , , ,


Eisai and Biogen Idec have entered into a pharma deal to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401. Read the full story

Settlement agreement reached between pharma alliances, Mylan

Tags: , , , , ,


Mylan Pharmaceuticals and pharma alliances, Banner Pharmacaps have entered into a settlement and license agreement with Eisai and Valeant Pharmaceuticals. Read the full story